linagliptin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 31 Diseases   34 Trials   34 Trials   1690 News 


«12345678910111213...1819»
  • ||||||||||  HSK7653 / Haisco
    Trial completion:  HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) -  Dec 12, 2022   
    P3,  N=465, Completed, 
    In conclusion, linagliptin is a promising anti-virulence and anti-QS candidate that can be used solely or in combination with traditional antimicrobial agents in the treatment of P. aeruginosa aggressive infections. Recruiting --> Completed
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Journal:  A growth selection system for the directed evolution of amine-forming or converting enzymes. (Pubmed Central) -  Dec 4, 2022   
    This results in (i) an amine transaminase variant with 110-fold increased specific activity for the asymmetric synthesis of the chiral amine intermediate of Linagliptin; (ii) a 270-fold improved monoamine oxidase to prepare the chiral amine intermediate of Cinacalcet by deracemization; and (iii) an ammonia lyase variant with a 26-fold increased activity in the asymmetric synthesis of a non-natural amino acid. Our growth selection system is adaptable to different enzyme classes, varying levels of enzyme activities, and thus a flexible tool for various stages of an engineering campaign.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Journal:  An In-Silico Identification of Potential Flavonoids against Kidney Fibrosis Targeting TGFβR-1. (Pubmed Central) -  Nov 16, 2022   
    ADME/T screening identified a total of 31 flavonoids with drug-like properties of 31 compounds, a total of 5 compounds showed a higher binding affinity to TGFβR-1, with Epicatechin, Fisetin, and Luteolin ranking at the top three (-13.58, -13.17, and -10.50 kcal/mol, respectively), which are comparable to the control drug linagliptin (-9.074 kcal/mol)...These findings indicate that flavonoids, particularly Epicatechin, Fisetin, and Luteolin, may compete with the ligand-binding site of TGFβR-1, suggesting that these compounds can be further evaluated for the development of potential therapeutics against kidney fibrosis. Further, in-vitro and in-vivo studies are recommended to support the current findings.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Linagliptin. (Twitter) -  Nov 14, 2022   
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Tradjenta ? (Twitter) -  Nov 14, 2022   
  • ||||||||||  Effects of newer antidiabetic agents on cardiovascular outcomes in older adults: systematic review and meta-analysis () -  Oct 30, 2022 - Abstract #CMHC2022CMHC_14;    
    These trials have played an important role in the paradigm shift from the gluco-centric diabetes management to one in which the risk for CV disease becomes the deciding factor for the next therapeutic steps. Older adults with diabetes are a uniquely heterogenous group with a high prevalence of comorbidities as well as high risk for hypoglycemia, which has been reported to increase risk of CV events.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Onglyza (saxagliptin) / AstraZeneca, Januvia (sitagliptin) / Merck (MSD)
    Clinical, Journal:  Bullous Pemphigoid Associated with Dipeptidyl Peptidase 4 Inhibitors for the Treatment of Type 2 Diabetes: A Multicenter Study in Istanbul. (Pubmed Central) -  Oct 29, 2022   
    The most common prescribed oral antidiabetic for both groups was metformin...Fourteen (24.1%) out of 58 diabetic patients with BP were using vildagliptin, 12 (20.7%) out of 58 diabetic BP patients were using linagliptin, 6 (10.3%) out of 58 diabetic BP patients were using sitagliptin, and 1 (1.7%) out of 58 diabetic BP patients were using saxagliptin...BP patients using DPP4i had statistically less mucosal involvement than BP patients not using DPP4i (p=0.044). Even though there was no difference between two groups, when BP develops in diabetic patients, DPP4 is should be questioned and with cooperation with clinician's consideration of change may be planned.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Journal:  Efficacy of Yishen Huashi Granules Combined with Linagliptin Tablets on Blood Glucose and Renal Function in Patients with Type 2 Diabetic Nephropathy. (Pubmed Central) -  Oct 7, 2022   
    There were no patients in complete remission between both the groups, where slight differences were found in the proportion of significant remission (P > 0.05), with the total effective rate of the research group remarkably higher than that of the control group (P < 0.05). The combination of Yishen Huashi granules and linagliptin tablets can reduce the blood glucose and blood lipid levels in patients with type 2 DN and lower UPro and protect renal function at the same time, which provides a new idea and a method for clinical treatment of type 2 DN with integrated traditional Chinese and Western medicine.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Concomitant medication (conmed) interactions with novel hormonal agents (NHAs) in metastatic castration resistant prostate cancer (mCRPC) (Hall 407) -  Oct 1, 2022 - Abstract #ESMOAsia2022ESMO_Asia_317;    
    Table: 160MO Common interacting drug classes and culprit drugs Drug Class Patients on drug class, n Interacting Drug AA interaction ENZ interaction Statin 93 AtorvastatinSimvastatin CC Antiplatelet 63 Clopidogrel D Anticoagulant 32 ApixabanRivaroxabanWarfarin DDD Diuretic 44 SpironolactoneFrusemideHydrochlorothiazideIndapamide XCCC CCC Beta blocker 44 BisoprololMetoprololNebivololPropranololSotalol CCCD C CD Calcium channel blocker 38 FelodipineLercanidipineNifedipineDiltiazemVerapamil DCDDD Anti-arrhythmic 9 AmiodaroneDigoxinFlecainide D C DDC Hypoglycaemic 30 GliclazideGlimepirideLinagliptin CCD Opioid 56 BuprenorphineCodeineFentanylOxycodoneTramadol C C CCCCC Anti epileptic 32 CarbamazepineSodium valproate D DC Conclusions In our real-world cohort, potential conmed interactions with NHAs were common, involving routinely prescribed drug classes. Poorer outcomes in patients with significant conmed interactions highlight the importance of conmed review in treatment selection.
  • ||||||||||  Sugarnon (evogliptin) - Dong / A
    Clinical, Retrospective data, Review:  The efficacy and safety of evogliptin for type 2 diabetes mellitus: A systematic review and meta-analysis. (Pubmed Central) -  Sep 14, 2022   
    P = 0.966) regarding the adverse effects, indicating no significant difference between evogliptin and linagliptin or sitagliptin in affecting the HbA1c level and adverse effects. The study provides preliminary evidence regarding the similarity in the efficacy of evogliptin compared to other DPP-4i drugs, including sitagliptin and linagliptin, for managing HbA1c levels and adverse events.
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Biomarker, Preclinical, Journal, Combination therapy:  Linagliptin in Combination With Metformin Ameliorates Diabetic Osteoporosis Through Modulating BMP-2 and Sclerostin in the High-Fat Diet Fed C57BL/6 Mice. (Pubmed Central) -  Aug 13, 2022   
    Interestingly, treatment with linagliptin and its combination with metformin significantly reverted the impaired bone architecture, BMD, and positively modulated bone turnover biomarkers, while metformin alone did not exhibit any significant improvement. Further, HFD induced diabetes and metabolic abnormalities (including an increase in body weight, FBG, impaired glucose and insulin tolerance, leptin, triglycerides, cholesterol), and pro-inflammatory cytokines (TNF-alpha and IL-1β) were successfully reversed by treatment with linagliptin, metformin, and their combination. Linagliptin and its combination with metformin successfully ameliorated diabetic osteoporosis in HFD-fed mice possibly through modulation of BMP-2 and sclerostin. The study provides the first evidence for the possible use of linagliptin and metformin combination for managing diabetic osteoporosis.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Byetta (exenatide) / AstraZeneca
    Review, Journal:  Olfactory dysfunction in type II diabetes: Therapeutic options and lessons learned from other etiologies - A scoping review. (Pubmed Central) -  Aug 5, 2022   
    Additionally, treatments for OD related to non-DM2-associated etiologies, such as olfactory training, are well-studied, efficacious, and should be investigated in the context of DM2. Future investigation has the potential to enhance the quality of clinical intervention for OD and improve short- and long-term outcomes for DM2 patients.
  • ||||||||||  Review, Journal:  A Narrative Review of Diabetic Kidney Disease: Previous and Current Evidence-Based Therapeutic Approaches. (Pubmed Central) -  Jul 28, 2022   
    Additionally, incretin-based therapeutic agents, such as glucagon-like peptide 1, liraglutide (LEADER), and dipeptidyl peptidase 4 inhibitors, linagliptin (CARMERINA) have elicited vasotropic actions, suggesting a potential for reducing the risk of DKD...In contrast, finerenone, a non-steroidal MRA, significantly reduced renal composite endpoint without severe hyperkalemia that would force its discontinuation (FIDELIO-DKD). Thus, the mainstay treatments of DKD are RAS inhibitors, SGLT2 inhibitors, incretin-based therapeutic agents, and non-steroidal MRA, or in other words, the DKD "fantastic four".
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly, Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    Enrollment change, Trial withdrawal:  Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus. (clinicaltrials.gov) -  Jul 27, 2022   
    P3,  N=0, Withdrawn, 
    Thus, the mainstay treatments of DKD are RAS inhibitors, SGLT2 inhibitors, incretin-based therapeutic agents, and non-steroidal MRA, or in other words, the DKD "fantastic four". N=660 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Intestinal microbiota composition in patients with type 2 diabetes and effects of 12 weeks of oral anti-diabetic treatment (ENDOExpo, Pod 3) -  Jul 16, 2022 - Abstract #ENDO2022ENDO_2702;    
    After 12 weeks of treatment (receiving oral antidiabetic treatment, metformin or linagliptin), at genera level, Lactobacillus, Rothia and Collinsella increased in type 2 diabetes group however, microbiota composition was still different compared to the healthy controls...Learning Objective 1: The aim of the study was to evaluate intestinal microbiota composition in patients with type 2 diabetes. Science Topic(s) for Diabetes and Glucose Metabolism: Diabetes Clinical Care
  • ||||||||||  Piqray (alpelisib) / Novartis
    Control of Alpelisib-Induced Hyperglycemia With DPP4- Inhibitors as add on to Metformin and Insulin () -  Jul 16, 2022 - Abstract #ENDO2022ENDO_1329;    
    This case report illustrates the course of development of high blood glucose in a patient with breast cancer treated with alpelisib, and the treatment approach employed. Linagliptin, an oral glucose lowering drug commonly used in diabetes mellitus, is used together with metformin and insulin therapy, to control the blood glucose in this patient.
  • ||||||||||  Zyclara (imiquimod) / Mochida, Viatris, Bausch Health, Tradjenta (linagliptin) / Boehringer Ingelheim, Eli Lilly
    Preclinical, Journal:  DPP-4 inhibitor linagliptin ameliorates imiquimod-induced psoriasis-like skin alterations in type 2 diabetic mice by inhibiting the MAPK/NF-κB inflammatory pathway. (Pubmed Central) -  Jun 25, 2022   
    The underlying mechanism of this compound may be related to the inhibition of MAPK/NF-κB inflammatory pathways and the consequential improvement of insulin resistance.Significance Statement: In this study, we evaluated the therapeutic effect of the DPP-4 inhibitor linagliptin using a murine model of type 2 diabetes combined with psoriasis, and its potential mechanisms of action were further explored. The results of this study will help to uncover the pathogenesis of type 2 diabetes and psoriasis and, more importantly, provide a theoretical basis for the search for safe and effective drugs in the treatment of this specific patient population.
  • ||||||||||  Trial completion, Trial completion date, Bariatric surgery:  Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment (clinicaltrials.gov) -  Jun 23, 2022   
    P4,  N=40, Completed, 
    The results of this study will help to uncover the pathogenesis of type 2 diabetes and psoriasis and, more importantly, provide a theoretical basis for the search for safe and effective drugs in the treatment of this specific patient population. Unknown status --> Completed | Trial completion date: Dec 2020 --> Jun 2022